Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human beta-defensin 3 - PubMed (original) (raw)
Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human beta-defensin 3
Zhibin Wu et al. Proc Natl Acad Sci U S A. 2003.
Abstract
Human defensins form a family of small, cationic, and Cys-rich antimicrobial proteins that play important roles in innate immunity against invading microbes. They also function as effective immune modulators in adaptive immunity by selectively chemoattracting T lymphocytes and immature dendritic cells. On the basis of sequence homology and the connectivity of six conserved Cys residues, human defensins are classified into alpha and beta families. Structures of several beta-defensins have recently been characterized, confirming the disulfide connectivity conserved within the family, i.e., Cys1-Cys5, Cys2-Cys4, and Cys3-Cys6. We found that human beta-defensin 3 (hBD3), a recently described member of the growing beta family, did not fold preferentially into a native conformation in vitro under various oxidative conditions. Using the orthogonal protection of Cys1-Cys5 and of Cys1-Cys6, we chemically synthesized six topological analogs of hBD3 with predefined disulfide connectivities, including the (presumably) native beta pairing. Unexpectedly, all differently folded hBD3 species exhibited similar antimicrobial activity against Escherichia coli, whereas a wide range of chemotactic activities was observed with these analogs for monocytes and cells transfected by the chemokine receptor CCR6. Furthermore, whereas substitution of all Cys residues by alpha-aminobutyric acid completely abolished the chemotactic activity of hBD3, the bactericidal activity remained unaffected in the absence of any disulfide bridge. Our findings demonstrate that disulfide bonding in hBD3, although required for binding and activation of receptors for chemotaxis, is fully dispensable for its antimicrobial function, thus shedding light on the mechanisms of action for human beta-defensins and the design of novel peptide antibiotics.
Figures
Figure 1
Fig. 1.
(A) Folding of hBD1 and hBD2 aided by cysteine/cystine. Fully reduced, purified peptides were analyzed by C18 RP-HPLC (thin lines) with a linear gradient of 5–65% acetonitrile over 30 min. Peptides folded after 24 h (thick lines) were analyzed under the same chromatographic conditions. (B) Folding of hBD3 under various oxidative conditions: DMSO, air, and cysteine/cystine. Analyses by C18 RP-HPLC were carried out using a linear gradient of 20–35% acetonitrile over 30 min.
Fig. 2.
(A) Strategy for preparation of six topological analogs of hBD3. Fully reduced hBD3 peptides with Cys1/Cys5 or Cys1/Cys6 selectively protected by Acm were subjected to oxidative folding aided by cysteine/cystine, resulting in six intermediate products (a–f), each containing two disulfide bridges. After determination of the disulfide connectivity in each species, deprotection and spontaneous oxidation of Cys1/Cys5 or Cys1/Cys6 were achieved by treatment with I2 at pH 4. (B) Formation of two disulfide bridges in Cys1/Cys5- or Cys1/Cys6-protected hBD3. C18 RP-HPLC analyses were performed using a linear gradient of 5–65% acetonitrile over 30 min. All six resultant oxidation products of identical masses, a–f, were pooled for identification of the disulfide connectivity. The minor peak between species a and_b_ was a partially oxidized product with only one disulfide bridge formed as indicated by ESI-MS. (C) Analysis of the six purified topological analogs of hBD3 with defined disulfide connectivities on C18 RP-HPLC running a linear gradient of 5–65% acetonitrile over 30 min. Note that the order of elution changes upon formation of the third disulfide bridge.
Fig. 3.
Salt dependence of antimicrobial activity of linear and disulfide bridged hBD3 against E. coli. Oxidized hBD3 and [Abu]-hBD3 were assayed against E. coli ATCC 25922 at a fixed concentration of 20 μg/ml, as described in Materials and Methods, except that NaCl at concentrations noted in the figure were included in the assay buffer (10 mM potassium phosphate, pH 7.4).
Fig. 4.
Comparative analysis of synthetic hBD3 with the β topology and commercial hBD3 (1 μg each) on a Vydac C18 RP column (4.6 × 150 mm). The chromatographic data were collected using a linear gradient of 20–35% acetonitrile over 30 min.
Similar articles
- Structure-function analysis of Avian β-defensin-6 and β-defensin-12: role of charge and disulfide bridges.
Yang M, Zhang C, Zhang X, Zhang MZ, Rottinghaus GE, Zhang S. Yang M, et al. BMC Microbiol. 2016 Sep 9;16(1):210. doi: 10.1186/s12866-016-0828-y. BMC Microbiol. 2016. PMID: 27613063 Free PMC article. - Role of individual disulfide bridges in the conformation and activity of spinoxin (α-KTx6.13), a potassium channel toxin from Heterometrus spinifer scorpion venom.
Yamaguchi Y, Peigneur S, Liu J, Uemura S, Nose T, Nirthanan S, Gopalakrishnakone P, Tytgat J, Sato K. Yamaguchi Y, et al. Toxicon. 2016 Nov;122:31-38. doi: 10.1016/j.toxicon.2016.09.013. Epub 2016 Sep 19. Toxicon. 2016. PMID: 27660193 - Novel synthetic, salt-resistant analogs of human beta-defensins 1 and 3 endowed with enhanced antimicrobial activity.
Scudiero O, Galdiero S, Cantisani M, Di Noto R, Vitiello M, Galdiero M, Naclerio G, Cassiman JJ, Pedone C, Castaldo G, Salvatore F. Scudiero O, et al. Antimicrob Agents Chemother. 2010 Jun;54(6):2312-22. doi: 10.1128/AAC.01550-09. Epub 2010 Mar 22. Antimicrob Agents Chemother. 2010. PMID: 20308372 Free PMC article. - The human beta-defensin-3, an antibacterial peptide with multiple biological functions.
Dhople V, Krukemeyer A, Ramamoorthy A. Dhople V, et al. Biochim Biophys Acta. 2006 Sep;1758(9):1499-512. doi: 10.1016/j.bbamem.2006.07.007. Epub 2006 Jul 21. Biochim Biophys Acta. 2006. PMID: 16978580 Review. - Structure-activity relationships in beta-defensin peptides.
Taylor K, Barran PE, Dorin JR. Taylor K, et al. Biopolymers. 2008;90(1):1-7. doi: 10.1002/bip.20900. Biopolymers. 2008. PMID: 18041067 Review.
Cited by
- Interaction and dynamics of chemokine receptor CXCR4 binding with CXCL12 and hBD-3.
Penfield J, Zhang L. Penfield J, et al. Commun Chem. 2024 Sep 13;7(1):205. doi: 10.1038/s42004-024-01280-6. Commun Chem. 2024. PMID: 39271963 Free PMC article. - Research progress on the microbiota in bladder cancer tumors.
Lou K, Chi J, Wu J, Ma J, Liu S, Cui Y. Lou K, et al. Front Cell Infect Microbiol. 2024 Apr 8;14:1374944. doi: 10.3389/fcimb.2024.1374944. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38650736 Free PMC article. Review. - Understanding the Dynamics of Human Defensin Antimicrobial Peptides: Pathogen Resistance and Commensal Induction.
Kumaresan V, Kamaraj Y, Subramaniyan S, Punamalai G. Kumaresan V, et al. Appl Biochem Biotechnol. 2024 Mar 13. doi: 10.1007/s12010-024-04893-8. Online ahead of print. Appl Biochem Biotechnol. 2024. PMID: 38478321 Review. - PM2.5 Causes Increased Bacterial Invasion by Affecting HBD1 Expression in the Lung.
Zheng T, Wang Y, Zhou Z, Chen S, Jiang J, Chen S. Zheng T, et al. J Immunol Res. 2024 Jan 27;2024:6622950. doi: 10.1155/2024/6622950. eCollection 2024. J Immunol Res. 2024. PMID: 38314088 Free PMC article. - Potential Regulatory Gene Network Associated with the Ameliorative Effect of Oat Antibacterial Peptides on Rat Colitis.
Wang H, Chi X, Zhang D. Wang H, et al. Foods. 2024 Jan 11;13(2):236. doi: 10.3390/foods13020236. Foods. 2024. PMID: 38254536 Free PMC article.
References
- Nizet, V., Ohtake, T., Lauth, X., Trowbridge, J., Rudisill, J., Dorschner, R. A., Pestonjamasp, V., Piraino, J., Huttner, K. & Gallo, R. L. (2001) Nature 414, 454–457. - PubMed
- Zasloff, M. (2002) Nature 415, 389–395. - PubMed
- Hancock, R. E. W. & Lehrer, R. (1998) Trends Biotechnol. 16, 82–88. - PubMed
- Lehrer, R. I. & Ganz, T. (2002) Curr. Opin. Immunol. 14, 96–102. - PubMed
- Ganz, T. & Lehrer, R. I. (1998) Curr. Opin. Immunol. 10, 41–44. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources